Discovery and structure-activity relationship of quinuclidine benzamides as agonists of α7 nicotinic acetylcholine receptors

Journal of Medicinal Chemistry

Volumn 48, Issue 4, 2005, Pages 905-908

  Bodnar, Alice L ^a   Cortes Burgos, Luz A ^a   Cook, Karen K ^a   Dinh, Dac M ^a   Groppi, Vincent E ^a   Hajos, Mihaly ^a   Higdon, Nicole R ^a   Hoffmann, William E ^a   Hurst, Raymond S ^a   Myers, Jason K ^a,b   Rogers, Bruce N ^a   Wall, Theron M ^a   Wolfe, Mark L ^a   Wong, Erik ^a  

^a PFIZER INC   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 4 METHOXYBENZAMIDE; 5 NITROBENZAMIDE; AMPHETAMINE; AR R17779; BENZAMIDE DERIVATIVE; CHIMERIC PROTEIN; METHYLLYCACONITINE; NICOTINE; NICOTINIC AGENT; NICOTINIC ALPHA7 RECEPTOR AGONIST; PNU 282987; QUINUCLIDINE BENZAMIDE DERIVATIVE; QUINUCLIDINE CARBAMATE DERIVATIVE; QUINUCLIDINE DERIVATIVE; SEROTONIN 3 RECEPTOR; SULPIRIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUDITORY GATING DEFICIT; CELL ASSAY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; IC 50; NONHUMAN; RAT; SENSORY DYSFUNCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZAMIDES; CELLS, CULTURED; COMBINATORIAL CHEMISTRY TECHNIQUES; HIPPOCAMPUS; ION CHANNEL GATING; NEURONS; NICOTINIC AGONISTS; PATCH-CLAMP TECHNIQUES; QUINUCLIDINES; RADIOLIGAND ASSAY; RATS; RECEPTORS, NICOTINIC; RECEPTORS, SEROTONIN, 5-HT3; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 13944267447     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049363q     Document Type: Article

References (39)

1. (a) Picciotto, M. R.; Caldarone, B. J.; King, S. L.; Zachariou, V. Nicotinic Receptors in the Brain; Links between Molecular Biology and Behavior. Neuropsychopharmacology 2000, 22, 451-465.
2. (b) Dani, J. A. Overview of nicotinic receptors and their roles in the central nervous system. Biol. Psychiatry 2001, 49, 166-174.
3. (c) Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities; Arneric, S. P., Brioni, J. D., Eds.; Wiley-Liss: New York, 1999.
4. (d) Handbook of Experimental Pharmacology: Neuronal Nicotinic Receptors; Clementi, F., Fornasari, D., Gotti, C., Eds.; Springer: New York, 2000.
5. Weiland, S.; Bertrand, D.; Leonard, S. Neuronal nicotinic acetylcholine receptors: from the gene to the disease. Behav. Brain Res. 2000, 113, 43-56.
6. (a) Séguéla, P.; Wadiche, J.; Dineley-Miller, K.; Dani, J. A.; Patrick, J. W. Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J. Neurosci. 1993, 13, 596-604.
7. (b) Levin, E. D.; Simon, B. B. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology 1998, 138, 217-230.
8. (a) Adler, L. E.; Hoffer, L. D.; Wiser, A.; Freedman, R. Normalization of Auditory Physiology by Cigarette Smoking in Schizophrenic Patients. Am. J. Psychiatry 1993, 150, 1856-1861.
9. (b) Normalizing Effects of Nicotine and a Novel Nicotinic Agonist on Hippocampal Auditory Gating in Two Animal Models. Pharm. Biol. Behav. 1997, 57, 869-874.
10. (c) Stevens, K. E.; Kem, W. R.; Mahnir, V. M.; Freedman, R. Selective alpha(7)-nicotinic agonists normalize inhibittion of auditory response in DBA mice. Psychopharmacology 1998, 136, 320-327.
11. Nagamoto, H. T.; Adler, L. E.; McRae, K. A.; Huettl, P.; Cawthra, E.; Gerhardt, G.; Hea, R.; Griffith, J. Auditory P50 in schizophrenics on clozapine: Improved gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenylglycol. Neuropsychobiology 1999, 39, 10-17.
12. For leading reviews in this area, see the following: (a) Bunnelle, W. H.; Dart, M. J.; Schrimpf, M. R. Design of ligands for the nicotinic acetylcholine receptors: The quest for selectivity. Curr. Med. Chem. 2004, 4, 299-334.
13. (b) Romanelli, M. N.; Gualtieri, F. Cholinergic nicotinic receptors: Competitive ligands, allosteric modulators, and their potential applications. Med. Res. Rev. 2003, 23, 393-426.
14. (c) Astles, P. C.; Baker, S. R.; Boot, J. R.; Broad, L. M.; Dell, C. P.; Keenan, M. Recent progress in the development of subtype selective nicotinic acetylcholine receptor ligands. Curr. Drug Targets: CNS Neurol. Disord. 2002, 1, 337-348.
15. (d) Schmitt, J. D. Exploring the Nature of Molecular Recognition in Nicotinic Acetylcholine Receptors. Curr. Med. Chem. 2000, 7, 749-800.
16. (e) Holladay, M. W.; Dart, M. J.; Lynch, J. K. Neuronal Nicotinic Acetylcholine Receptors as Targets for Drug Discovery. J. Med. Chem. 1997, 40, 4169-4194.
17. (f) Glennon, R. A.; Dukat, M. Nicotinic Receptor Ligands. Med. Chem. Res. 1996, 465-486
18. (a) Eisele, J.; Bertrand, S.; Galzi, J.; Devillers-Thiery, A.; Changeux, J.; Bertrand, D. Chimeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specificities. Nature 1993, 366, 479.
19. (b) Groppi, V. E.; Wolfe, M. L.; Berkenpas, M. B. Methods and Compositions for Measuring Ion Channel Conductance. WO 00/073431, December 7, 2000.
20. 4 receptor activities of dihydrobenzofuran carboxylic acid derivatives. Bioorg. Med. Chem. Lett. 1996, 6, 263-266.
21. 3) antagonists. Curr. Med. Chem: Cent. Nerv. Syst. Agents 2001, 1, 171-199.
22. 3 receptor antagonists. Expert Opin. Pharmacother. 2000, 1, 207-23.
23. 3 receptors. Med. Res. Rev. 1990, 10, 441-475.
24. (a) Meyer, E. M.; Tay, E. T.; Papke, R. L.; Meyers, C.; Huang, G.-L.; de Fiebre, C. M. 3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat alpha7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner. Brain Res. 1997, 768, 49-56.
25. 125I-bungarotoxin receptor subtypes. Mol. Pharmacol. 1995, 47, 164-171.
26. Mullen, G.; Napier, J.; Balestra, M.; DeCory, T.; Hale, G.; Macor, J.; Mack, R.; Loch, J.; Wu, E.; Kover, A.; Verhoest, P.; Sampognaro, A.; Phillips, E.; Zhu, Y.; Murray, R.; Griffith, R.; Blosser, J.; Gurley, D.; Machulskis, A.; Zongrone, J.; Rosen, A.; Gordon, J. (-)-Spiro[1-azabicyclo[2.2.2]octane-3, 5′-oxazolidin-2′-one], a Conformationally Restricted Analog of Acetylcholine, Is a Highly Selective Full Agonist at the α7 Nicotinic Acetylcholine Receptor. J. Med. Chem. 2000, 43, 4045-4050.
27. (a) Macor, J.; Wu, E. Azabicyclic esters of carbamic acids useful in therapy. PCT Int. Appl. WO9730998, August 28, 1997.
28. (b) Guendisch, D.; Andrae, M.; Munoz, L.; Tilotta, M. C. Synthesis and evaluation of phenylcarbamate derivatives as ligands for nicotinic acetylcholine receptors. Bioorg. Med. Chem. 2004, 12, 4953-4962.
29. 3 antagonist tropisetron was reported to contain α7 activity. Macor, J. E.; Gurley, D.; Lanthorn, T.; Loch, J.; Mack, R. A.; Mullen, G.; Tran, O.; Wright, N.; Gordon, J. C. The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective α7 nicotinic receptor partial agonist. Bioorg. Med. Chem. Lett. 2001, 11, 319-321.
30. Kiso, Y.; Yajima, H. Peptides; Academic Press: San Diego, CA, 1995; pp 39-91.
31. Ward, J. M.; Cockcroft, V. B.; Lunt, G. G.; Smillie, F. S.; Wonnacott, S. Methyllycaconitine: a selective probe for neuronal alpha-bungaro-toxin binding sites. FEBS Lett. 1990, 270, 45-48.
32. Palma, E.; Bertrand, S.; Binzoni, T.; Bertrand, D. Neuronal nicotinic alpha 7 receptor expressed in Xenopus oocytes presents five putative binding sites for methyllycaconitine. J. Physiol. 1996, 15, 1511-1561.
33. (a) Sullivan, J. P.; Bannon, A. W. Epibatidine: Pharmacological Properties of a Novel Nicotinic Acetylcholine Receptor Agonist and Analgesic Agent. CNS Drug Rev. 1996, 2, 21-39.
34. (b) Brioni, J. D.; Morgan, S. J.; O'Niell, A. B.; Sykora, T. M.; Postl, S. P.; Pan, J. B.; Sullivan, J. P.; Arneric, S. P. "In Vivo" Profile of Novel Nicotinic Ligands with CNS Selectivity. Med. Chem. Res. 1996, 487-510.
35. Pabreza, L. A.; Dhawan, S.; Kellar, K. J. [3H]cytisine binding to nicotinic cholinergic receptors in brain. Mol. Pharmacol. 1991, 39, 9-12.
36. 3 receptor antagonist [3H]GR65630 to rat cortical membranes. Neurochem. Int. 1993; 22, 547-553
37. (a) Stevens, K. E.; Luthman, J.; Lindqvist, E.; Johnson, R. G.; Rose, G. M. Effects of neonatal dopamine depletion on sensory inhibition in the rat. Pharmacol. Biochem. Behav. 1996, 53, 817-823.
38. (b) Krause, M.; Hoffmann, W. E.; Hajos, M. Auditory Sensory Gating in Hippocampus and Reticular Thalamic Neurons in Anaesthetized Rats. Biol. Psychiatry 2003, 53, 244-253.
39. (c) Hajós, M.; Hurst, R. S.; Hoffmann, W. E.; Krause, M.; Wall, T. M.; Higdon, N. R.; Groppi, V. E. The Selective α7 nAChR Agonist PNU-282987 Enhances GABAergic Synaptic Activity in Brain Slices and Restores Auditory Gating Deficits in Anesthetized Rats. J. Pharmacol. Exp. Ther., in press.